ATE432275T1 - Pyrrol- bzw. imidazolamide zur behandlung von obesitas - Google Patents
Pyrrol- bzw. imidazolamide zur behandlung von obesitasInfo
- Publication number
- ATE432275T1 ATE432275T1 AT05735382T AT05735382T ATE432275T1 AT E432275 T1 ATE432275 T1 AT E432275T1 AT 05735382 T AT05735382 T AT 05735382T AT 05735382 T AT05735382 T AT 05735382T AT E432275 T1 ATE432275 T1 AT E432275T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- imidazolamide
- obesitas
- pyrrole
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04102005 | 2004-05-10 | ||
| PCT/EP2005/004416 WO2005108393A1 (en) | 2004-05-10 | 2005-04-25 | Pyrrole or imidazole amides for treating obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432275T1 true ATE432275T1 (de) | 2009-06-15 |
Family
ID=34965432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05735382T ATE432275T1 (de) | 2004-05-10 | 2005-04-25 | Pyrrol- bzw. imidazolamide zur behandlung von obesitas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7563910B2 (de) |
| EP (1) | EP1749002B1 (de) |
| JP (1) | JP2007536298A (de) |
| KR (1) | KR100870346B1 (de) |
| CN (1) | CN1950361A (de) |
| AT (1) | ATE432275T1 (de) |
| AU (1) | AU2005240734A1 (de) |
| BR (1) | BRPI0510679A (de) |
| CA (1) | CA2564986A1 (de) |
| DE (1) | DE602005014632D1 (de) |
| ES (1) | ES2324720T3 (de) |
| MX (1) | MXPA06012813A (de) |
| RU (1) | RU2380367C2 (de) |
| WO (1) | WO2005108393A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006074445A2 (en) * | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
| CA2642619A1 (en) * | 2006-02-20 | 2007-08-30 | Astellas Pharma Inc. | Pyrrole derivative or salt thereof |
| WO2007106721A2 (en) * | 2006-03-10 | 2007-09-20 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
| PT2239253E (pt) * | 2008-02-06 | 2013-09-17 | Daiichi Sankyo Co Ltd | Novo derivado de fenilpirrole |
| EP2800745B1 (de) | 2011-12-02 | 2020-02-12 | Phenex Pharmaceuticals AG | Pyrrolocarboxamid-verbindungen als modulatoren von mit orphan-nuklearrezeptor rar zusammenhängender orphan-rezeptor-gamma-aktivität (rory-nr1f3-aktivität) und zur behandlung chronischer entzündungs- und autoimmunerkrankungen |
| JO3215B1 (ar) * | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| WO2024073497A2 (en) * | 2022-09-27 | 2024-04-04 | University Of Florida Research Foundation, Incorporated | Small molecule degraders of hiv-1 tat protein |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940418A (en) | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| PT1169312E (pt) | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Activadores de glicocinase |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| AU2001234958A1 (en) * | 2000-02-11 | 2001-08-20 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| ATE346047T1 (de) | 2000-03-23 | 2006-12-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer aktivität |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| JP2002210238A (ja) * | 2001-01-24 | 2002-07-30 | Sony Computer Entertainment Inc | 記録媒体、プログラム、プログラム実行システム及びプログラム実行装置 |
| AU2002319627A1 (en) * | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| MXPA04002438A (es) | 2001-09-24 | 2004-06-29 | Bayer Pharmaceuticals Corp | Preparacion y uso de derivados de pirroll para el tratamiento de la obesidad. |
| AR036608A1 (es) | 2001-09-24 | 2004-09-22 | Bayer Corp | Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad |
| AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
-
2005
- 2005-04-25 EP EP05735382A patent/EP1749002B1/de not_active Not-in-force
- 2005-04-25 AU AU2005240734A patent/AU2005240734A1/en not_active Abandoned
- 2005-04-25 RU RU2006143596/04A patent/RU2380367C2/ru not_active IP Right Cessation
- 2005-04-25 AT AT05735382T patent/ATE432275T1/de active
- 2005-04-25 WO PCT/EP2005/004416 patent/WO2005108393A1/en active Application Filing
- 2005-04-25 CA CA002564986A patent/CA2564986A1/en not_active Abandoned
- 2005-04-25 JP JP2007511942A patent/JP2007536298A/ja active Pending
- 2005-04-25 DE DE602005014632T patent/DE602005014632D1/de active Active
- 2005-04-25 BR BRPI0510679-6A patent/BRPI0510679A/pt not_active IP Right Cessation
- 2005-04-25 CN CNA2005800147749A patent/CN1950361A/zh active Pending
- 2005-04-25 ES ES05735382T patent/ES2324720T3/es active Active
- 2005-04-25 MX MXPA06012813A patent/MXPA06012813A/es active IP Right Grant
- 2005-04-25 KR KR1020067023490A patent/KR100870346B1/ko not_active IP Right Cessation
- 2005-05-09 US US11/125,382 patent/US7563910B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006143596A (ru) | 2008-06-20 |
| US7563910B2 (en) | 2009-07-21 |
| AU2005240734A1 (en) | 2005-11-17 |
| CN1950361A (zh) | 2007-04-18 |
| DE602005014632D1 (de) | 2009-07-09 |
| BRPI0510679A (pt) | 2007-12-26 |
| JP2007536298A (ja) | 2007-12-13 |
| MXPA06012813A (es) | 2007-01-26 |
| CA2564986A1 (en) | 2005-11-17 |
| WO2005108393A1 (en) | 2005-11-17 |
| EP1749002B1 (de) | 2009-05-27 |
| US20050250769A1 (en) | 2005-11-10 |
| ES2324720T3 (es) | 2009-08-13 |
| KR100870346B1 (ko) | 2008-11-25 |
| RU2380367C2 (ru) | 2010-01-27 |
| EP1749002A1 (de) | 2007-02-07 |
| KR20070009686A (ko) | 2007-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| ATE517882T1 (de) | Chinolinderivate | |
| EA201070422A1 (ru) | Производные оксадиазола | |
| RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| ATE432275T1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| EA201000098A1 (ru) | Производные хиназолинамида | |
| DE602006017980D1 (de) | 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| ATE384058T1 (de) | Thiazolderivate | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| ATE466854T1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
| EA201100872A1 (ru) | Производные хиназолинамида | |
| DE602007011434D1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| DE602005007765D1 (de) | Neue indol- oder benzimidazol-derivate | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1749002 Country of ref document: EP |